We are live on ! Find out more
CANF

Can-Fite BioPharma American Depositary Shares

12 hedge funds and large institutions have $1.52M invested in Can-Fite BioPharma American Depositary Shares in 2024 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

9% more funds holding

Funds holding: 1112 (+1)

0% less ownership

Funds ownership: 0%0% (-0%)

6% less capital invested

Capital invested by funds: $1.62M → $1.52M (-$103K)

Holders
12
Holders Change
+1
Holders Change %
+9.09%
% of All Funds
0.17%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
3
Increased
2
Reduced
1
Closed
2
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
AC
1
Armistice Capital
New York
$1.31M +$351K +6,557 +25%
Morgan Stanley
2
Morgan Stanley
New York
$102K -$45.9K -857 -25%
TSS
3
Two Sigma Securities
New York
$59.4K +$79.2K +1,479 New
RhumbLine Advisers
4
RhumbLine Advisers
Massachusetts
$34.1K +$4.12K +77 +10%
Fifth Third Bancorp
5
Fifth Third Bancorp
Ohio
$6.03K
Wells Fargo
6
Wells Fargo
California
$5.03K +$6.69K +125 New
National Bank of Canada
7
National Bank of Canada
Quebec, Canada
$1.21K
Citigroup
8
Citigroup
New York
$1.11K
AWM
9
Activest Wealth Management
Florida
$402
Osaic Holdings
10
Osaic Holdings
Arizona
$372
TWC
11
TD Waterhouse Canada
Ontario, Canada
$38
HF
12
HRT Financial
New York
-$27K -540 Closed
VF
13
Virtu Financial
New York
-$27K -521 Closed
AW
14
Avion Wealth
Texas
+$268 +5 New

CANF Hedge Fund Activity: Q3 2024 in Review

12 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Can-Fite BioPharma American Depositary Shares (CANF) for Q3 2024, worth a combined $1.52M — down 6.4% from $1.62M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new CANF positions and 2 closed out — a net gain of 1 holder — while 2 added to existing stakes and 1 trimmed.

The largest buyer was Armistice Capital, adding an estimated $351K. The largest seller was Morgan Stanley, cutting an estimated $45.9K.

  • 12 institutional investors held Can-Fite BioPharma American Depositary Shares (CANF) as of Q3 2024, up from 11 in Q2 2024.
  • Funds reported $1.52M of Can-Fite BioPharma American Depositary Shares stock for Q3 2024, down 6.4% quarter-over-quarter.
  • 3 funds opened new Can-Fite BioPharma American Depositary Shares positions in Q3 2024 and 2 closed out, a net change of +1 holder.
  • The largest Can-Fite BioPharma American Depositary Shares buyer in Q3 2024 was Armistice Capital, an estimated $351K added.
  • The largest Can-Fite BioPharma American Depositary Shares seller in Q3 2024 was Morgan Stanley, an estimated $45.9K sold.

Based on aggregated 13F filings for Q3 2024.